ABBV vs KO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Coca-Cola Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
The Coca-Cola Company · Consumer Defensive
$84.92
-10.2% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
KO trades at a lower forward P/E
(26.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
KO |
| Current Price |
$261.07 |
$84.92 |
| Fair Value Estimate |
$264.30 |
$76.30 |
| Upside to Fair Value |
+1.2%
|
-10.2%
|
| Market Cap |
$461.3B |
$365.4B |
| Forward P/E |
128.0x
|
26.6x
|
| EV / EBITDA |
31.0x
|
20.7x
|
| Price / Sales |
7.3x
|
7.4x
|
| Price / FCF |
22.1x
|
29.1x
|
| Revenue Growth YoY |
+12.4%
|
+12.1%
|
| Gross Margin |
70.7%
|
61.7%
|
| Operating Margin |
27.6%
|
29.3%
|
| Return on Equity |
68.0%
|
43.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
3.44%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
The Coca-Cola Company is a leading global beverage company specializing in non-alcoholic drinks with a durable competitive moat driven by its strong brand and extensive distribution network. The business quality is high, evidenced by a 43.6% return on equity, robust gross margin of 61.7%, and solid revenue and earnings growth of 12.1% and 17.8% respectively in the most recent quarter. Despite the…
Accumulation Zones
| Metric |
ABBV |
KO |
| Zone Low |
$198.23 |
$57.22 |
| Zone High |
$224.66 |
$64.85 |
| In Buy Zone? |
No
|
No
|